Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3.6% – What’s Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was down 3.6% on Tuesday . The company traded as low as $0.22 and last traded at $0.23. Approximately 15,196,699 shares traded hands during mid-day trading, a decline of 75% from the average daily volume of 60,758,266 shares. The stock had previously closed at $0.24.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research report on Friday, January 17th. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Stock Performance

The stock has a fifty day simple moving average of $0.27 and a 200-day simple moving average of $0.29. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $61.21 million, a P/E ratio of -0.01 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The company had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. Equities analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC acquired a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned about 0.12% of Tonix Pharmaceuticals at the end of the most recent reporting period. 82.26% of the stock is owned by institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.